COVID-19: CDC, FDA and CMS Guidance
This page includes AHA Today stories and other AHA content on coronavirus COVID-19 guidance from the CDC, FDA, and CMS.
The Centers for Disease Control and Prevention issued interim guidelines for serologic methods used for monitoring and responding to the COVID-19 pandemic.
CMS issued a rule finalizing certain telehealth and network adequacy proposals for Medicare Advantage and Part D prescription drug plans for contract years 2021 and 2022, as well as certain provisions of the Bipartisan Budget Act of 2018 and 21st Century Cures Act, among other changes. The agency…
The Food and Drug Administration approved two abbreviated new drug applications expected to alleviate shortages and help during the COVID-19 emergency.
The FDA updated two guidances for the temporary compounding of certain drugs used to treat COVID-19 patients.
The FDA posted a list of COVID-19 antibody tests that will no longer be marketed because they have not been authorized for emergency use under its revised policy, or the manufacturer withdrew them from the list of tests under review for emergency use.
The CDC issued revised guidance for pediatric clinicians on caring for newborns with confirmed or suspected COVID-19 or known COVID-19 exposure, including birth to a mother with confirmed or suspected COVID-19.
To facilitate tracheal intubation and provide skeletal muscle relaxation during surgery or mechanical ventilation, the Food and Drug Administration approved the use of succinylcholine chloride injection USP 200 mg/10 mL.
The CDC has released a framework for providing non-COVID-19 clinical care during the pandemic, based on the level of community transmission and potential for patient harm from deferring in-person care.
CMS said that until Medicare sets national payment rates for COVID-19-related testing claims, its Medicare Administrative Contractors have authority to set payment amounts in their respective jurisdictions.
In response to the significant impact of the COVID-19 pandemic on nursing homes, the Centers for Medicare & Medicaid Services recommended criteria for state and local officials who are considering how to mitigate risks.